Literature DB >> 20495576

The colony-stimulating factors and cancer.

Donald Metcalf1.   

Abstract

The four colony-stimulating factors (CSFs) are glycoproteins that regulate the generation and some functions of infection-protective granulocytes and macrophages. Recombinant granulocyte-CSF (G-CSF) and granulocyte-macrophage-CSF (GM-CSF) have now been used to increase dangerously low white blood cell levels in many millions of cancer patients following chemotherapy. These CSFs also release haematopoietic stem cells to the peripheral blood, and these cells have now largely replaced bone marrow as more effective populations for transplantation to cancer patients who have treatment-induced bone marrow damage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20495576      PMCID: PMC3345291          DOI: 10.1038/nrc2843

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  153 in total

1.  Differentiation commitment and regulator-specific granulocyte-macrophage maturation in a novel pro-B murine leukemic cell line.

Authors:  Y Laâbi; D Metcalf; S Mifsud; L Di Rago
Journal:  Leukemia       Date:  2000-10       Impact factor: 11.528

2.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation.

Authors:  J Nemunaitis; J W Singer; C D Buckner; D Durnam; C Epstein; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

Review 3.  Haematological recovery after high-dose consolidation chemotherapy with peripheral blood progenitor cell rescue: the effects of the mobilization regimen and post-transplant growth factors.

Authors:  M E Van Hoef
Journal:  Neth J Med       Date:  1998-01       Impact factor: 1.422

4.  The growth of mouse bone marrow cells in vitro.

Authors:  T R Bradley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1966-06

5.  Partial purification and some properties of the factor in normal and leukaemic human urine stimulating mouse bone marrow colony growth in vitro.

Authors:  E R Stanley; D Metcalf
Journal:  Aust J Exp Biol Med Sci       Date:  1969-08

6.  In vitro control of the development of macrophage and granulocyte colonies.

Authors:  Y Ichikawa; D H Pluznik; L Sachs
Journal:  Proc Natl Acad Sci U S A       Date:  1966-08       Impact factor: 11.205

7.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies.

Authors:  J Nemunaitis; J W Singer; C D Buckner; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

8.  Murine megakaryocyte progenitor cells and their susceptibility to suppression by G-CSF.

Authors:  Donald Metcalf; Sandra Mifsud; Ladina Di Rago
Journal:  Stem Cells       Date:  2005       Impact factor: 6.277

9.  SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis.

Authors:  Ben A Croker; Donald Metcalf; Lorraine Robb; Wei Wei; Sandra Mifsud; Ladina DiRago; Leonie A Cluse; Kate D Sutherland; Lynne Hartley; Emily Williams; Jian-Guo Zhang; Douglas J Hilton; Nicos A Nicola; Warren S Alexander; Andrew W Roberts
Journal:  Immunity       Date:  2004-02       Impact factor: 31.745

10.  Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.

Authors:  H H Gerhartz; M Engelhard; P Meusers; G Brittinger; W Wilmanns; G Schlimok; P Mueller; D Huhn; R Musch; W Siegert
Journal:  Blood       Date:  1993-10-15       Impact factor: 22.113

View more
  58 in total

1.  Characterization of thrombopoietin (TPO)-responsive progenitor cells in adult mouse bone marrow with in vivo megakaryocyte and erythroid potential.

Authors:  Ashley P Ng; Maria Kauppi; Donald Metcalf; Ladina Di Rago; Craig D Hyland; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  Translating G-CSF as an Adjunct Therapy to Stem Cell Transplantation for Stroke.

Authors:  Ike dela Peña; Cesar V Borlongan
Journal:  Transl Stroke Res       Date:  2015-12       Impact factor: 6.829

3.  Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia.

Authors:  Kathrin Steinwede; Ole Tempelhof; Kristine Bolte; Regina Maus; Jennifer Bohling; Bianca Ueberberg; Florian Länger; John W Christman; James C Paton; Kjetil Ask; Shyam Maharaj; Martin Kolb; Jack Gauldie; Tobias Welte; Ulrich A Maus
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

Review 4.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

5.  Tumor entrained neutrophils inhibit seeding in the premetastatic lung.

Authors:  Zvi Granot; Erik Henke; Elizabeth A Comen; Tari A King; Larry Norton; Robert Benezra
Journal:  Cancer Cell       Date:  2011-09-13       Impact factor: 31.743

Review 6.  Hematopoiesis.

Authors:  Michael A Rieger; Timm Schroeder
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-12-01       Impact factor: 10.005

7.  Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States.

Authors:  Lisa A Raedler
Journal:  Am Health Drug Benefits       Date:  2016-03

8.  Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling.

Authors:  Manikandan Subramanian; Edward Thorp; Ira Tabas
Journal:  Circ Res       Date:  2014-10-27       Impact factor: 17.367

Review 9.  The colony-stimulating factors and cancer.

Authors:  Donald Metcalf
Journal:  Cancer Immunol Res       Date:  2013-12       Impact factor: 11.151

10.  Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response.

Authors:  Jiusheng Deng; Shala Yuan; Andrea Pennati; Jordan Murphy; Jian Hui Wu; David Lawson; Jacques Galipeau
Journal:  Cancer Res       Date:  2014-06-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.